Rigel Pharmaceuticals

Update in progress

RIGL (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Rigel Pharmaceuticals is a biotechnology company focused on therapies for hematologic disorders and cancer. It markets TAVALISSE (fostamatinib) for adult chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for IDH1-mutant relapsed/refractory AML, and GAVRETO (pralsetinib) for RET fusion–positive NSCLC and thyroid cancer. It is developing R289 (IRAK1/4 inhibitor) for hematology-oncology, autoimmunity, and inflammation. Partnerships include MD Anderson and CONNECT, and it is based in South San Francisco, founded in 1996.

Company score

Sentiment: 0.06; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.07; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive